RREB-1 Is a Transcriptional
The nonclassical HLA-G is a molecule specifically involved in immune tolerance with highly restricted tissue distribution in healthy conditions. Yet it is overexpressed in numerous tumors and in allografts with better acceptance. Major mechanisms involved in regulation of HLA-G transcription are still poorly described. Thus, to characterize these mechanisms we have developed a specific proteomic approach to identify proteins that bind differentially to the HLA-G gene promoter by promoter pull-down assay followed by spectrometry mass analysis. Among specific binding factors, we focused on RREB-1, a ras-responsive element binding protein 1. We demonstrated that RREB-1 represses HLA-G transcriptional activity and binds three ras response elements within the HLA-G promoter. RREB-1 protein, specifically in HLA-G-negative cells, interacts with subunits of CtBP complex implicated in chromatin remodeling. This demonstration is the first of a repressor factor of HLA-G transcriptional activity taking part in HLA-G repression by epigenetic mechanisms. The Journal of Immunology, 2009, 183: 6948 -6959.
T he HLA-G molecule is a nonclassical HLA class I molecule proposed to play an important role in immune tolerance, particularly in the maternal immunological accommodation of the fetus (1) . Despite a mounting number of publications, data on HLA-G function and tissue distribution have described both well-established features and unresolved questions (2) .
Evidences have been accumulated showing that HLA-G inhibits the NK (3) and T lymphocyte-mediated direct cytotoxicity (4) . It also inhibits the proliferative allogenic response (5) through interaction with inhibitory receptors ILT2/CD85j/LILRB1 (6) and ILT4/CD85d/LILRB2 (7) . Whether KIR2DL4/CD158d (8) is expressed in vivo and can bind HLA-G is still unclear (2) .
In nonpathological conditions, the expression of HLA-G proteins is restricted. HLA-G is detected in a few fetal tissues, which include cytotrophoblasts and amnion of the placenta (9, 10 ) and a few healthy adult tissues, including thymus (11), cornea (12) , pancreas (13) , and erythroblasts (14) . Nonetheless, because all HLA-I molecules share 80% amino acid, cross-reactivity to the other HLA by HLA-G Abs has been hypothesized for studies in which biochemical analysis to identify the 39-kD H chain of HLA-G was not done. However, the surface expression of HLA-G expression in vivo is consistently and reproducibly detected in extravillous trophoblasts with all anti-HLA-G Ab and by varied techniques. HLA-G expression is also reported in pathological conditions. HLA-G is found in numerous tumors and then would favor malignant cell development by impairing antitumor immunity (15, 16) . However, it is of note that there is controversy about some of these findings based on means of detecting specific HLA-G expression. HLA-G is also observed in biopsy samples and sera of patients undergoing transplantation and is associated with a reduced number of rejection episodes (17, 18) . Notably, the presence of stable HLA-G protein expression is correlated with high levels of HLA-G transcripts, whereas its absence in almost all nonpathological situations is correlated with low level or absence of HLA-G transcripts (19, 20) . Thus, the understanding of molecular mechanisms that regulate HLA-G transcription is crucial.
HLA-G gene promoter structure and mRNA have been previously published (21) (22) (23) and are reported in the NCBI database. HLA-G gene consists of exon 1 (5Ј-ATG) encoding the signal peptide, exons 2, 3, and 4 encoding ␣1, ␣2, and ␣3 extracellular domains, respectively and exon 5 encoding transmembrane domain and a very short cytoplasmic tail together with exon 6. A major feature of HLA-G is the alternative splicing of primary transcript that deletes specific exons or retains introns, thus giving rise to seven proteins isoforms (24 -26) . Promoter regions have been initially defined by comparison with classical HLA-I gene promoters (27, 28) include transcriptional control of classical HLA class I genes (HLA-A, HLA-B, and HLA-C) and ␤ 2 -microglogulin genes, which are mediated by a conserved cis-acting regulatory element scattered through the region named "proximal promoter." These major regulatory elements include CCAAT and unusual TATA (TCTTAA) elements controlling basal regulation and a transcriptional initiation site located 25-bp downstream of TATA, that are conserved in HLA-G. Nonetheless, a second putative initiation site of HLA-G transcription can be observed 51-bp upstream of TATA (CTCACTCCC), but its functionality is not currently demonstrated. Other regulatory elements are enhancer A, IFN-stimulated response element, and the SXY module, which is crucial for the constitutive and CIITA-mediated HLA class I gene transactivation (27, 29) . HLA class I-acting regulatory elements (except S1 and X1 boxes) are disrupted within the HLA-G gene proximal promoter region rendering this gene unresponsive to NF-B, IFN regulatory factor 1, and CIITA-mediated induction pathways (30, 31) .
HLA-G gene transcriptional machinery has been poorly described even if some of the mechanisms that govern HLA-G transcriptional activity have been identified (23 3 has been found located Ϫ1.2 kb from the ATG translation start site (20, (32) (33) (34) (named "distal promoter" region). A few HLA-G promoter binding factors and their target sites have been characterized such as CREB1 (28) , IFN regulatory factor 1 (35) , heat shock transcription factor 1 (36), or progesterone receptor (37) . Microenvironmental parameters have been shown to play a key role in the modulation of HLA-G gene, including stress conditions such as heat shock (36) or hypoxia (38) , cytokines such as IFN (35, 39) , IL-10 (40), leukemia inhibitory factor (41), GM-CSF (42) , and hormones such as glucocorticoids (43) or progesterone (44) . However, for most of them the mechanism of action remains unknown. Recently, we provided evidence for cis-acting epigenetic mechanisms like CpG methylation and histone deacetylation involved in HLA-G gene response (45, 46) . The recruitment of repressor regulatory mechanisms in HLA-G negative cells and the possible presence of negative regulatory factors have been considered (20, 30, 34) but no corepressor factor has yet been determined.
In an attempt to better understand the regulatory mechanisms that participate in physiological and pathological expression of HLA-G, we have developed a strategy to isolate and characterize protein complexes implied in HLA-G gene transcriptional machinery. We used a comparative proteomic approach to identify proteins that bind differentially to the HLA-G gene promoter by promoter pull-down assay, followed by spectrometry mass analysis. This search led to the identification of ras-responsive element binding protein 1 (RREB-1) in protein extracts from HLA-G-negative cells. We provide evidence of the role of RREB-1 in repression of HLA-G transcription through the recruitment of C-terminal binding protein (CtBP)1, CtBP2, or both and histone deacetylase (HDAC)1, which are subunits of CtBP complex, a corepressor involved in chromatin remodeling. Ours results further propose that repressive activity of RREB-1 on HLA-G promoter may be regulated by posttranslational modifications that govern association with CtBP.
Materials and Methods

Plasmids
The plasmids encoding for RREB-1 were a gift from A. Leiter (University of Massachusetts Medical School, Worcester, MA). The p1400 Luciferase (1438 bp of HLA-G promoter) and p500 Luciferase (500 bp of HLA-G promoter) reporter gene have been previously described (46) . Mutated rasresponsive element (RRE) sites were introduced within the p1400 luciferase using complementary mutated oligonucleotides carrying the same mutations as in EMSA. Site-directed mutagenesis of the three RREB-1 binding sites was performed by MilleGen. Mutated plasmid p1400 RREmut-Luc was verified by sequencing.
Human cell line culture
The chroriocarcinoma cell line JEG-3 (American Type Culture Collection) and HeLa cell line were grown in DMEM supplemented with Glutamax-I, 4500 mg/L glucose (Invitrogen), 10% FCS (BioWhittaker), 1000 U of penicillin, and 10 g/ml streptomycin. The melanoma cell line M8 and the Burkitt's lymphoma B cell line Raji were maintained in RPMI 1640 (SigmaAldrich) supplemented with 2 mM L-glutamine (Sigma-Aldrich), 10% FCS (Biowhittaker), 1000 U of penicillin, and 10 g/ml streptomycin. All cultures were maintained at 37°C and 5% CO 2 .
Whole cell extracts obtained by freeze-thaw cycles
Cells (ϳ50 million) were pelleted, washed with ice cold PBS, and resuspended in two packed cell volumes of a buffer containing 50 mM HEPES (pH 7.9), 400 nM KCl, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 2 mM DTT, 5 g/ml leupeptin (Sigma-Aldrich), 1 mM PMSF (Roche Diagnostics), 0.5 mM Na 3 VO 4 , and 0.5 mM sodium fluoride and protease inhibitor mix (Complete; Roche Diagnostics). Cell extracts were obtained by three successive freeze-thaw cycles, snap frozen in liquid nitrogen and stored at Ϫ80°C. Protein extracts were cleared by centrifugation and stored at Ϫ80°C.
Promoter pull down assays
Promoter pull-down assays were performed as described (47) (Fig. 1A) . Briefly, promoter templates biotinylated at the 5Ј end of the upper strand were generated by PCR using primers HLA-G (forward) 5Ј-biot-CCCGCGTTGGGGATTCTCTC and (reverse) 5Ј-ATGAGTCCGGGTGG GTGAGC. Specificity of PCR products (20 pmol) was verified by sequencing (Genoscreen). Templates were coupled to 900 g of streptavidincoated magnetic beads (Streptavidin Paramagnetic Particle; Promega). Whole cell extracts (7 mg, 400 -600 l) from Raji or JEG cells were first preincubated for 30 min at 4°C with 1500 g of paramagnetic beads (nonspecific binding on beads) in a buffer containing 20 mM HEPES (pH 7.9), 20% glycerol, 9 mM MgCl 2 , 0.1 mM EDTA, 0.01% Nonidet P-40, 0.15 mg/ml polydeoxyinosinic-polydeoxycytidylic acid (Amersham Biosciences), heat denaturated salmon sperm DNA (Invitrogen), and protease inhibitor mix (Complete; Roche Diagnostics). After discarding of beads, the supernatant was incubated with DNA template in the same buffer for over 2 h at 4°C with agitation. Beads were washed three times with the same buffer containing 1 mg/ml BSA. Proteins were eluted with 140 l of buffer containing 9 M deionized urea (Bio-Rad), 4.4% CHAPS (SigmaAldrich), 5 mM tributylphosphine (Sigma-Aldrich), 0.22% Bio-Lyte 3-10 (Bio-Rad), and traces of bromophenol blue. After 1 h of incubation at room temperature, beads were discarded.
Two-dimensional gel electrophoresis
The supernatant was directly applied to IPG-Strip (pH 3-10; Bio-Rad) by 14 -16 h rehydration at 20°C. Proteins were focused successively on Protean IEF Cell (Bio-Rad) during two steps: a desalting period because the current raise to 250 V, followed by a rapid ramping to 8000 V for 10,000 Volthours without exceeding 50 A per IPG-Strip. Focused IPG strips were equilibrated for 15 min in a solution (6 M urea, 2% SDS, 20% glycerol, 375 mM Tris-HCl (pH 8.8), and 2% DTT) and then for an additional 15 min in the same solution except that DTT was replaced by 2.5% iodoacetamide (Bio-Rad) and trace bromophenol blue. After equilibration, two-dimensional SDS-PAGE was performed on Ettan DALT II system.
Gel scanning and image analysis
After SDS-PAGE, the gel was colored with Sypro ruby solution (Bio-Rad) overnight after 30 min fixing in 40% ethanol-10% acetic acid solution, 1 h in 10% ethanol-7% acetic acid, followed by 1 h in ultrapure water. Gel picture was captured on UV plate with a camera imager (Appligen) (Fig.  1 , B and C) and analyzed, and relevant spots were excised.
Protein identification by MALDI-TOF
Selected differential protein spots were excised from preparative gels reduced in 1-mm 3 fragments and in-gel trypsin digestion was performed. The gels spots were washed during 5 min with two-distillation water and destained with a fresh solution containing 100 mM NH 4 HCO 3 in 50% acetonitrile at 37°C for 5 min. After being dried with a speed-vac, gel fragments were incubated in digestion solution consisting of 100 mM NH 4 CO 3 , and 10 mM DTT at 56°C for 30 min, then rinsed with acetonitrile for 15 min, and incubated in 100 mM NH 4 HCO 3 , 55 mM iodoacetamide in the dark for an additional 20 min at 37°C before being dehydrated in acetonitrile and dryed with speed-vac. Fragments were rehydrated 40 min on ice in digestion solution contained 25 mM NH 4 CO 3 , 0.04% CaCl 2 , 0.01% TFA, and 6 g/ml trypsin-modified Sequencing Grade (Roche) for 2 h at 37°C. Action of the trypsin was inactivated with formic acid. The tryptic peptide mixture was extracted by a 10 min sonication and purified with Millipore ZIP-TIP C18 column (Millipore) following suppliers instructions. The purified tryptic peptide mixture was resuspended in 3 l of 1% formic acid. A 0.5 l of the mixture was mixed with one volume of solution containing saturated CCA (␣-cyano-4-hydroxycinnamic; SigmaAldrich) as solution in 50:50 TFA 0.1% to acetonitril) or 2,5 dihydroxybenzoic acid (Sigma-Aldrich) as solution in 9:1 TFA 0.1% to ethanol. The 1 l of the mixture CCA matrix was loaded on a stainless steel plate, air-dried, and analyzed with mass spectrometer. The standard peptide mixture (des-arg bradykinin, angiotensin, neurotensin, ACTH 18 -39, ACTH 7-38) was spotted at the same time to correct the machine. Analysis were performed in positive mode with reflectron, using a 20,000 V acceleration tension, a 200 ns held extraction using a mean of 350 laser pulses on a mass range between 650 and 4000 Da.
Mass spectra were recorded in the reflectron positive mode of a MALDI-TOF mass spectrometer (DE-STRE Voyager; Applera Applied Biosystems) by summing 350 laser shots with an acceleration voltage of 20 kV, 200-ns delay. MALDI-TOF peptides mass maps were processed using the peptide mass fingerprinting analysis software ProFound (129.85.19.192/prowl-cgi/ProFound.exe). The NCBInr and Swissprot databases were used for the searches with several passes of searching with different limitations for each spots. In general, all spots were searched with methionine oxidation, no limitation for isoelectric point, and with the following parameters to find the best match: two missed cut cleavages, limited to the "mammal category", or a set with or without 50% of total molecular mass, alkylation partial chemical modifications, protonization charge, and 0.15 Da mass precision.
Transient transfection and luciferase activity assays
One day before transfection, cells were plated in 6-well plates with 50 -60% confluence. Each well was transfected using Exgen 500 reagent (Fermentas) according to the manufacturer's instructions, with a DNA mixture including 1 g of firefly luciferase reporter gene containing HLA-G promoter, 50 ng of a control plasmid tk-luciferase (tk-Renilla; Promega) and the indicated concentration of pCDNA-RREB-1. After 24 h of transfection, cells were harvested and luciferase activity was assayed with Bright-Glo luciferase assays System and Renilla luciferase assays system (Promega) using a luminometer (Lumar LB 9507; EG & G Berthold). Firefly luciferase values were normalized to those of Renilla luciferase values. Assays were run in duplicate, triplicate or more (two, three, or more independent experiments, respectively, each was performed as technical duplicate). In experiments in which RNA silencing analysis was performed, luciferase activity was assayed 48 h following small interference RNA (siRNA) transfection. In such a situation cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions, first with siRNA and second (t ϭ 24 h) with recombinant plasmids containing reporter genes.
RNA silencing
For RNA interference experiments, we used ON-TARGET plus SMART pool siRNA oligonucleotides (Dharmacon), a predesigned siRNA reagent against different splice variants of RREB-1. A siRNA control encoding scrambled sequence was used as control. siRNA were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Real-time RT-PCR analysis
RNA extraction, DNase I treatment, reverse transcription and real-time RT-PCR, were conducted as previously described (45, 46) . Duplex PCR was performed with GAPDH as an endogenous control, HLA-G specific primers selected to amplify all alternative forms of HLA-G transcripts and a HLA-G-specific probe located in exon 5.
Cellular extracts preparation, immunoprecipitation, and Western blot
Cellular extract preparation and Western blot analyses were conducted as previously described (34) . Immunoprecipitation assays were performed as described (48) . Immunodetections were performed using the following Abs: anti-RREB-1 from Rockland; anti-HDAC1 (H-51), anti-CtBP (E-12 FIGURE 1. Representative two-dimensional gel electrophoresis (2-DE) pattern of protein extracts selected on HLA-G proximal promoter by pull-down assay. A, Strategy developed for the identification of HLA-G promoter binding proteins by combining proteomic to DNA affinity. B and C, Two-dimensional gel electrophoresis obtained with Raji protein extracts (negative HLA-G transcription) on the left (B) and JEG-3 protein extracts (positive HLA-G transcription) on the right (C) in at least two independent experiments. Protein extracts were used in promoter pull-down assays conducted with 170 bp fragment of HLA-G proximal promoter fragment (location of primers are in Fig. 4 ). Gels were stained with Sypro ruby solution using isoelectric focusing (IEF). Spots in boxes are the ones found at the same locations in gels obtained with control experiments using magnetic beads without DNA fragment to identify nonspecific protein binding to the matrix. Specific protein spots are indicated (arrowhead with number). MALDI-TOF analysis of spot 7 and spot 10 identified NF-Y and RREB-1 (Table I) factors, respectively. detects CtBP1 and CtBP2), and control rabbit IgG from Santa Cruz Biotechnology; anti-acetyl lysine (AB3879) from Chemicon; and monoclonal anti-␣ tubulin from Sigma-Aldrich.
EMSA analysis
The 2 l of nuclear extracts were incubated with ␥-32 P double-strand oligonucleotide probe (1-2 ng, 10 5 cpm) encompassing the RREs of HLA-G promoter, 2 g of polydeoxyinosinic-polydeoxycytidylic acid (Amersham Biosciences) in binding buffer containing 40 mM KCL, 20 mM HEPES (pH 7.5), 0.1 mM EGTA, 1 mM MgCl 2 , 0.5 mM DTT, and 0.4% Ficoll. The following oligonucleotides (Eurogentec) were used for probes: HE-443 5Ј-GGAACTTGAGAGAGGACCGAAGAGAAGCA and 5Ј-GCTTCTCTTCGGTCCTCTCTCAAGTTCC) (49); RRE-53 5Ј-AGCGTCGCCGCGGTCCTGGTTCTAAAG and 5Ј-CTTTAGAACC AGGACCGCGGCGACGCT); RRE-142 5Ј-AACCTGTGTCGGGTCC TTCTTCCTGGATACTCACCG and 5Ј-CGGTGAGTATCCAGGAAG AAGGACCCGACACAGGTT); and RRE-1356 5Ј-CTGACTCATAGT AGCAGGACCACTATAGAGAG and 5Ј-CTCTCTATAGTGGTCCTG CTACTATGAGTCAG). The following oligonucleotides with mutated RRE sites were: RRE-53mut AGCGTCGCCGCAAAAAAGGTTCTA AAG and CTTTAGAACCTTTTTTGCGGCGACGCT; RRE-142mut AA CCTGTGTCGAAAAAATCTAAAAAAATACTCACCG and CGGTGA GTATTTTTTTAGATTTTTTCGACACAGGTT; and RRE-1356mut CT GACTCATAGTAGTAGGTGTTTTTTAGAGAGandCTCTCTAAAAAA CACCTACTACTATGAGTCAG). Competition experiments were performed using 100-fold molar excess of cold probe. Complexes were separated by electrophoresis for 1-2 h at 200 V in 5% polyacrylamide gel (29:1 acrylamide to bisacrylamide ratio).
Combined Western blotting and EMSA
The assay WEMSA combines Western blotting and EMSA analyses (50) . Nuclear extracts and reaction mixtures are prepared as described for EMSA, except for the use of unlabeled oligonucleotides. After incubation for 30 min at room temperature, reaction mixtures were separated by nondenaturing PAGE, exactly as done for EMSA. The separated DNA-protein complexes were then transferred to nitrocellulose membranes and probed with anti-RREB-1, anti-HDAC1, and anti-CtBP Abs by Western blotting as described below.
Chromatin immunoprecipitation assays (ChIP)
ChIP assays were performed as previously described (51) using anti-RREB-1 from Rockland; anti-acetylated histone H3 (06-599) and antiphosphorylated Ser 10 histone H3 (07-081) from Upstate Biotechnology Associates; and anti-RNApolII (C-21) and anti-HDAC1 (H-51) from Santa Cruz Biotechnology. Briefly, formaldehyde cross-linked chromatin was sonicated and immunoprecipitated with either no Ab or the indicated Ab. ChIP analyses were performed at least in triplicate using distinct DNA preparations. Immunoprecipitated DNA was purified and quantified by regular PCR. The HLA-G promoter targeted sequences (Ϫ187; ϩ4) and (Ϫ1438; Ϫ1185) were amplified using the following primers: 5Ј-CCCG CGTTGGGGATTCTCTC-3Ј, 5Ј-AGAGGGTTCGGGGCGCCATGAC CAC-3Ј and 5Ј-AAGCTTCACAAGAATGAGGTGGAGCCACTGG-3Ј, 5Ј-TAAACCTAAGAGTTCCGCTGCT-3Ј, respectively.
Results
Identification of proteins that bind to the HLA-G proximal promoter by two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry analysis
To isolate and identify factors associated with the HLA-G gene promoter and implied in HLA-G expression, we initiated a comparative proteomic study of elements bound to the HLA-G gene promoter using protein extracts from HLA-G-positive JEG-3 cells and HLA-G-negative Raji cells. JEG-3 choriocarcinoma is a well-documented HLA-G-positive cellular model, commonly used in numerous studies on HLA-G expression. Raji (Burkitt's B lymphoma) was selected as a second model instead of the HLA-G-negative choriocarcinoma JAR because we first hypothesized that cell differences compared with JEG-3 would be more marked at the HLA-G gene promoter using cells both having strong different cellular origin and absence of HLA-G gene transcription. Moreover previous analysis of CpG methylation at the HLA-G gene promoter strongly suggested that HLA-G gene repression in JAR was principally governed by cis-acting DNA methylation (46) . Biotinylated, doubled stranded HLA-G proximal promoter fragments (170 bp) (see Fig. 4 ) obtained by PCR on human genomic DNA were verified by DNA sequencing (data not shown), and then incubated with protein extracts of HLA-Gpositive and HLA-G-negative cells. DNA affinity strategy was followed by two-dimensional gel electrophoresis separation, and proteins of interest were then digested by trypsin and analyzed by MALDI-TOF (Fig. 1A) . Representative two-dimensional gel electrophoresis results obtained from at least two independent experiments reveal both differential and shared DNA binding proteins by comparing HLA-G-positive (Fig. 1C) and HLA-G-negative (Fig. 1B) cell patterns. Among the shared proteins, some of them were considered nonspecific binding factors (surrounded spots) because they were also revealed by two-dimensional gel electrophoresis analysis performed with magnetic beads alone (data not shown). Mass matching analysis allowed the identification of one shared specific factor (spot 7, Fig. 1, B and C) , which corresponds to subunit C of NF-Y, a factor that binds the Y box (ATTGG) and CAAT-box motifs (52) . The later target site is present within the HLA-G bait fragment. In contrast, by analyzing the presence or absence and the intensity of protein spots in two-dimensional patterns obtained with HLA-G-positive and HLA-G-negative cells, we focused on spot 10 that exhibits great intensity in Raji cells only. MALDI-TOF mass spectrometry analysis revealed that the matched peptides cover 20% of the RREB-1 protein sequence. A complete list of RREB-1 peptides identified by mass matching is shown in Table I . Based on protein functions using (20, 30, 34) . Real-time RT-PCR analysis showed that steady state levels of HLA-G mRNA in HeLa cells were very low (ϳ1.5 10 Ϫ5 ) compared with HLA-G-positive choriocarcinoma JEG-3 cells (assigned a value of 1) (data not shown). Transfection experiments were done in triplicate using a luciferase reporter construct driven by promoter fragment encompassing either 1.4 or 0.5 kb upstream to the start codon of the HLA-G gene. In the absence of transfected RREB-1 we, respectively, observed a 12-fold (mean of two independent experiments) and a 5-fold (one experiment) increase in luciferase activity in comparison to the promoter-less control vector (data not shown). Moreover, as demonstrated in Fig. 2 for both plasmid constructs, cotransfection experiments performed with increasing doses of pCDNA-RREB1 plasmid resulted in the decrease of the reporter gene expression in a dose-dependent manner compared with cells transfected with empty pCDNA3 plasmid only. To further investigate the repressor effect of RREB-1, we followed a RNA interference approach using specific RREB-1 siRNA (vs control siRNA) transfected in HeLa cells 48 h before the analysis of luciferase activity. RREB-1 protein was decreased by 60 -70% when assayed by Western blot analysis of whole cell extracts (inset, Fig.  2B ). We repeated the luciferase experiments with 1.4-kb HLA-G promoter construction in HeLa cells in the presence of siRNA against RREB-1 mRNA. The transcriptional activity of the luciferase reporter gene was enhanced (2-fold) in RREB-1-depleted cells compared with control cells, and the enhancement was still observed in the presence of pCDNA3-RREB-1 (Fig. 2B) . To investigate more the HLA-G promoter activity in response to RREB-1 in different cell types, we performed luciferase reporter experiments with 1.4-kb promoter fragment and 0.5 g of pCDNA3-RREB-1 both in melanoma M8, another HLA-G-negative cell line (45, 46) , and in the HLA-G-positive choriocarcinoma JEG-3 cells. As expected luciferase gene expression in control conditions was higher in JEG-3 cells than in M8 cells reflecting differences in the transcriptional capacity of the cell lines. We observed a significant 23% mean decrease ( p Ͻ 0.05) in the luciferase reporter gene expression in M8 cells compared with M8 cells transfected with empty pCDNA3 plasmid, whereas the mean decrease was only 6% with JEG-3 cells (Fig. 3A) .
Moreover, to evaluate the effect of RREB-1 on endogenous HLA-G expression we investigated the amounts of HLA-G mRNA in HLA-G-negative M8 cells in the presence or absence of specific RREB-1 siRNA. In agreement with luciferase experiments we observed that the amounts of HLA-G mRNA was significantly enhanced (over 13-fold) after RREB-1 siRNA treatment compared with M8 cells treated with siRNA control encoding scrambled sequence, thus backing up the role of RREB-1 in the observed HLA-G gene repression (Fig. 3B) .
Because two-dimensional gel electrophoresis analysis showed a differential profile for RREB-1 spot between cells expressing (JEG-3) or not (Raji) HLA-G transcripts (Fig. 1) we wondered whether the expression of RREB-1 was specific of HLA-G-negative cells only. We thus performed a Western blot analysis using anti-RREB-1 polyclonal Ab with nuclear extracts of Raji, and melanoma M8, compared with HLA-G-positive JEG-3 cells. Unexpectedly, we noted no significant differences in the expression levels of RREB-1 regardless of the cell types we analyzed (Fig. 3C) . This may suggest that RREB-1 from JEG-3, which was not observed in two-dimensional gel electrophoresis pattern of JEG-3 at the position of spot 10, cannot bind proximal HLA-G promoter or exhibit posttranslational modifications such as phosphorylation or acetylation events affecting isoelectric point. Taken together, these results demonstrate that RREB-1 may act as a potential repressor factor of HLA-G transcription depending on cellular context. 1 g) . B, p1400-luciferase activity in the presence (ϩ) or not (Ϫ) of RREB-1 siRNA with (pCDNA3 RREB-1) or without (control) RREB-1 transfection plasmid (0.5 g). A and B, Empty pCDNA3 was added to make the total amount of DNA equal in all transfections. Normalized with Renilla luciferase, all data were expressed as a fold induction over the relative control (empty pCDNA3 plasmid), which was arbitrarily set to 1. Data represent mean Ϯ SD of determinations from three independent experiments. Representative Western blot analysis (inset) shows efficiency of RREB-1 siRNA. The ratio corresponds to the amount of RREB-1 protein normalized to tubulin protein. A value of 1 is assigned to the RREB-1 constitutive level.
HLA-G promoter region contains three functional RREB-1 target sites
The implication of RREB-1 protein in the modulation of HLA-G gene promoter activity prompted us to search for potential binding RRE sequences within the HLA-G gene promoter. We investigated the presence of the consensus DNA binding site CCCCACCATC-CCC obtained using the casting method (53) and the consensus ttk-related site GGTCCT corresponding to the binding site for LZ321, both sites were shown to bind RREB-1 with equal affinity (49) . We found three potential RREB-1 target sites along the 1.4-kb promoter sequence upstream to ATG (Fig. 4) : two putative binding sites are localized into the proximal promoter, one in position Ϫ70 to Ϫ44 that contains only one GGTCCT motif (RRE-53), and the second site in position Ϫ159 to Ϫ124 that contains one direct and one inverted GGTCCT motif (RRE-142). A third target site related to RREB-1 consensus binding sequence was found within the putative LCR (distal promoter), in position Ϫ1380 to Ϫ1346 (RRE-1356).
To investigate whether these HLA-G RRE sequences were direct targets for RREB-1, we performed EMSA first with Raji nuclear extracts and 32 P-labeled oligonucleotides corresponding to HLA-G probes RRE-53, RRE-142, and RRE-1356 (Fig. 5A) . Binding patterns were compared with the one of a control pattern obtained with RREB-1 and HE-443 probe (49) that reveal major specific complexes a. EMSA obtained with the three HLA-G RRE probes reveals a strong binding activity compared with the probe alone, with the presence of major DNA-protein complexes migrating at a similar positions than the control complexes a for each probes and a slower migrating complex b exhibiting lower intensity (Fig. 5B) . The binding DNA complexes were abolished in competition experiments using a 100-fold excess of cold RRE-site competitor (HE-443) (Fig. 5, lanes 8, 13, and 18) or the unlabeled probe itself (Fig. 5, lanes 4, 9, 14, and 19) . The specificity of RREB-1 DNA-binding was further confirmed as previously done (55) using nuclear extracts from Raji cells that were either immunodepleted with an Ab directed against RREB-1 or immunodepleted with rabbit IgG to control nonspecific loss of protein. In such a condition, DNA binding of RREB-1-depleted extracts was very weak or absent compared with the one we obtained using nonimmunoprecipitated fractions, thus giving a first demonstration for specific RREB-1 binding to the three HLA-G RREs (Fig. 5C) . Interestingly, EMSA patterns exhibit a few differences according to the oligonucleotide probe used (RRE-53, RRE-142, RRE-1356). This suggests that other factors than RREB-1 may contribute to the observed pattern as well. In agreement with this, we found a band that was present in the RRE-142 pattern even after immunodepletion with the RREB-1 Ab (arrows, Fig. 5C ). For example it is of note that the RRE-142 oligonucleotide contains the conserved HLA-G regulatory X1 box that was previously demonstrated to associate RFX factors in vitro (30, 31) .
To further evaluate the specificity of RREB-1 binding to the HLA-G RREs we performed competition experiments with labeled RRE oligonucleotide probes and 100-fold excess of unlabeled competitor oligonucleotides in which the RRE binding site has been mutated (RREmut) or not. These experiments were done both with nuclear extracts from Raji and M8 melanoma cells, which are negatives for HLA-G transcriptional activity. In accordance with previous results, EMSA revealed that most of complexes were displaced by addition of an excess of cold wild-type RRE oligonucleotides, whereas an excess of cold mutated RRE oligonucleotides did not significantly compete with probes (see supplemental Fig. 1) . 4 In addition, EMSA profiles obtained with nuclear extracts from HLA-G-negative cells were compared with EMSA profile from HLA-G-positive JEG-3 cells (Fig. 6) . By mean of this data, we noted that complexes a are always present in both cell types whatever HLA-G RRE probes used, whereas complex b is formed with all probes in HLA-G-negative cells and only with RRE-1356 probe (LCR location) incubated with JEG-3 extracts.
Next, to assess more the functionality of the HLA-G RREs we investigated the effect of RREB-1 overexpression using a luciferase reporter construct driven by a mutated 1.4 kb HLA-G promoter fragment (p1400 RREmut-Luc) in which the three RREB-1 binding sites have been scrambled. Cotransfection experiments performed in HeLa and M8 cells with 0.5 g of pCDNA3-RREB-1 (Fig. 7) showed that mutations of RRE sites preventing the binding of RREB-1 impaired the previously observed down-regulation of HLA-G promoter activity in Figs. 2 and 3 .
Finally, to confirm that the RREB-1 binding sites identified by EMSA are able to recruit RREB-1 in living cells, we performed ChIP assays both with M8 and JEG-3 cells (Fig. 8A) . As expected, RREB-1 proteins were tethered to the proximal and distal (LCR) promoter (Fig. 4) of HLA-G-negative cells. No precipitation was detected in an irrelevant region of HLA-G by RREB-1 Ab (data not shown). Interestingly RREB-1 was only found associated with the HLA-G distal promoter (LCR) in JEG-3 cells, a result agreeing on two-dimensional gel electrophoresis analysis in which spot 10 (RREB-1) was absent in gels obtained with JEG-3 protein extracts and proximal HLA-G promoter that contains RRE-53 and RRE-142 sequences (Fig. 4) . This result is also in accordance with the fact that complex b is exclusively observed with RRE-1356 oligonucleotide probe (within LCR) in EMSA performed with JEG-3 cell proteins.
RREB-1 can associate HDAC1 and CtBP components on the HLA-G gene promoter
We first wondered whether RREB-1 binding to the HLA-G promoter was associated or not with chromatin modifications involved in the repression of transcriptional activity. By analyzing M8 and JEG-3 cells we found that HDAC1 binding to the HLA-G gene promoter is restricted to M8 cells. In agreement on our previous results (46), we confirmed that histone H3 are constitutively acetylated and phosphorylated in JEG-3 cells, providing a chromatinized environment that allow the recruitment of RNA polymerase II on the transcription start site of HLA-G gene. In contrast, H3 histones are neither acetylated nor phosphorylated in M8 cells 4 The online version of this article contains supplemental material. Fig. 5 ). Sequences corresponding to oligonucleotide probes used for EMSA analysis (underlined), sequences corresponding to PCR primers used to generate promoter pull-down assay (double-underlined), and sequences corresponding to PCR primers used to amplify "proximal" and "distal" promoter (LCR) (bold and italic letters) are shown. CAAT and TATA sequences and ATG initiation site are boxed. (Fig. 8B) . These data suggest that deacetylation of H3 in M8 cells and the no-occupancy by RNA polII on the HLA-G promoter may be related to the recruitment of HDAC1 and may be associated with the interaction with RREB-1.
Because RREB-1 was previously detected in a CtBP corepressor complex we thus performed combined Western blotting and EMSA and supershift experiments with anti-RREB-1 Ab and Abs against relevant subunits of CtBP, namely anti-HDAC1 and antiCtBP1/2 (59). Using M8 nuclear extracts we observed that immunodetection of EMSA gel conducted with RRE-53 oligonucleotide probes and blotted to a nitrocellulose membrane (WEMSA) with each Abs revealed a smear and discrete bands migrating at the same position than those revealed with labeled RRE-53 probe. These results confirmed the presence of RREB-1 in complexes a and complex b and strongly suggest that HDAC1 and CtBP1/2 may participate in RREB-1 complexes (Fig. 9A) . In combined Western blotting and EMSA experiments it is noticeable that on top of discrete bands we observed smears testifying to the presence of HDAC1 and CtBP in a multitude of complexes in the cells. Nonetheless discrete bands indicate that HDAC1, CtBP1/2, and RREB1 are privileged partners (59) . These results are in agreement with supershift experiments performed with RRE-53 probe and anti-CtBP1/2 and anti-HDAC1 Abs (Fig. 9B ).
HDAC1 and CtBP1/2 are preferentially associated with RREB1 in M8 HLA-G-negative cells
To test whether HDAC1 and CtBP1/2 are interacting with RREB-1, we performed an immunoprecipitation assay using M8 lanes 2, 6, 11, and 16 ) or in the presence of a 400-fold molar excess of unlabeled competitors. RRE-53, RRE-142, and RRE-1356 fragments (lanes 9, 14, and 19, respectively), irrelevant fragment that differs from RRE (lanes 3, 7, 12, and 17) , and HE-443, which is a RREB-1 DNA binding control with GGTCCT motif (lanes 4, 8, 13 , and 18). Complexes a indicates the major specific RREB-1 binding activity. Complex b is analyzed in Fig. 7 . Arrows designate factors that differ from RREB-1. C, Depletion EMSA experiments with Ab-directed against RREB-1. Nuclear extracts from Raji cells were either RREB-1-depleted (RREB-1 Ϫ) or not (control IgG ϩ) and subsequently used in EMSA experiments with 32 P-labeled HLA-G probes HE-443, RRE-53, RRE-142, and RRE-1356. The amount of nuclear extracts used is indicated (1 g or 2 g ).
and JEG-3 nuclear extracts, HDAC1 and CtBP1/2 specific Abs. Western blot analysis targeting RREB-1 shows that HDAC1 and CtBP1/2 are present in RREB-1 containing complex (Fig. 10A ) and more particularly in M8 cells in comparison with JEG-3 cells (RREB-1 band at ϳ80 -90 kD is of the predicted molecular weight). In addition, RREB-1 acetylation has been tested in both cellular types by RREB-1 immunoprecipitation followed by Western blot using anti-acetylated lysine Ab. RREB-1 acetylation was clearly predominant in HLA-G-positive JEG-3 cells (Fig. 10B) .
Discussion
Previous studies have revealed very little shared functional regulatory sequences and binding factors between HLA-G and HLA class I genes (31) and only a few factors modulating HLA-G gene expression have been identified until now (18, 23) . We thus devised a strategy to isolate unidentified factor candidates implied in the transcriptional regulation of the HLA-G gene. This original approach combining HLA-G promoter pull-down experiments and mass spectrometry, allowed prediction of RREB-1 (53), a zinc finger transcription factor also named FinB (54), LZ321 (49) , and Zep-1. Because the factor is expressed ubiquitously in human tissues outside the adult brain (54, 60) , its presence in all cell types analyzed, namely Raji, M8, and JEG-3, is understandable at first sight.
Looking for RREB-1 function on the HLA-G gene transcription and associated mechanisms, we highlighted that overexpression and selective inhibition of expression of RREB-1 protein affect transcriptional activity driven by HLA-G promoter according to a repressive activity in HLA-G-negative cells. According to this, RREB-1 has been described to be implied in transcriptional repression of several genes such as p16INK4a (56) angiotensinogen (57) , and prostate-specific Ag (58) . Interestingly, RREB-1 was also described as a coactivator of calcitonin (53), c-erbB2 (54) , and secretin (55) genes, thus confirming that its normal cellular function is dependent on cellular context or probably also on promoter of genes. In agreement on that we found that RREB-1 repressive activity on the HLA-G promoter was reduced or absent in HLA-G-positive JEG-3 cells.
RREB-1 targets three binding sites identified dispersed through the HLA-G promoter and demonstrated not only to bind RREB-1 in vitro but also to drive the down-regulation of HLA-G promoter activity measured by luciferase reporter gene experiments. RRE-53 and RRE-142 are located within the proximal HLA-G promoter and respectively contain one and two GGTCCT sequences to which LZ321 was shown to bind (49) . A third RRE corresponding to the consensus sequence derived by the method of cyclic amplification and selection of target (53) has been found at position Ϫ1356 in the distal HLA-G promoter region which was proposed to be a putative locus control region, previously associated with the high regulation of HLA-G tissue-specific expression in transgenic mouse (32, 33) . Interestingly we observed by EMSA that RREB-1 is constitutively bound to the three HLA-G promoter RREs in cells expressing or not HLA-G. However two-dimensional gel electrophoresis pattern obtained with HLA-G-positive JEG-3 cell extracts and proximal promoter region revealed that the spot 10 corresponding to RREB-1 in Raji was absent. A plausible explanation would be that RREB-1 binding activity to the HLA-G promoter requires posttranslational modifications changing the physicochemical criteria of the protein (molecular mass and isoelectric point), as previously reported for numerous proteins (61) to exert its function. Presumably any change would be to isoelectric point as molecular mass changes have not been detected on Western blots. Moreover, a marked RREB-1 acetylation in HLA-G-positive JEG-3 cells in comparison with HLA-G-negative M8 cells strongly argues for that.
In agreement on the two-dimensional gel electrophoresis analysis, ChIP assays revealed the RREB-1 binding to the proximal HLA-G promoter (contains RRE-53 and RRE-142) in HLA-G-negative cells only. In contrast, EMSA obtained with JEG-3 and HLA-G-negative cell protein extracts were very similar and thus seemed contradictory results. Nevertheless we noted that complex b was not formed with JEG-3 extracts and probes containing proximal promoter RRE binding sites. Therefore, complex b could involve specific RREB-1 modifications or combination of factors responsible in the two-dimensional gel electrophoresis and ChIP-specific patterns. A second explanation would be that factors involved both in complexes a and b could not associate the HLA-G proximal promoter in JEG-3 chromatin environment. In this regard it is noteworthy that the location of RRE-53 site is very close to the TATA box and might be in the way of transcription initiation complex. In agreement, ChIP analysis did not found RNA pol II at the HLA-G promoter in HLA-G-negative M8 cells, whereas it was found at the HLA-G promoter in HLA-G-positive JEG-3 cells. In addition, the fact that promoter response to RREB-1 transfection was low or absent in JEG-3 cells clearly support such a hypothesis.
It is also noteworthy that we observed the distal promoter occupancy by RREB-1 in HLA-G-positive cells. One possible explanation of this result would be that RREB-1 binding to the LCR in JEG-3 is regulating the overall levels of HLA-G transcripts in JEG-3 cells, which is lower than the one observed in the melanoma cell line FON (46) . Another explanation would be that RREB-1 in JEG-3 exhibited specific modifications acting on its repressive activity. In such a condition specific RREB-1 modifications in JEG-3 cells might explain that the effect of RREB-1 transfection on the luciferase reporter gene expression was low in this cell type.
Indeed, the present work underlined the formation of a multiprotein complex present predominantly in HLA-G negative cells. A combined Western blotting and EMSA assay has revealed that this complex is constituted of RREB-1, the histone deacetylase HDAC1 and CtBP1/2. We also demonstrated by immunoprecipitate assays that RREB-1 interacts with HDAC1 and preferentially coimmunoprecipitates both with HDAC1 and CtBP1/2 in HLA-G-negative cells. Of great interest is that RREB-1, HDAC1, and CtBP1/2 are members of the nuclear protein complex CtBP core complex with CoREST, EHMT, ZEB1/2, or ZnF217 (59). CtBP is assembled by CtBP1 or CtBP2 and contains various enzymatic elements principally implied in modifications of histone (deacetylation and methylation) (62) , and particularly histone H3 Lys 9 (59) . Given that both HDAC and histone methyltransferase activities are associated with CtBP complex, it can facilitate stepwise, coordinated, enzyme reactions that convert an active chromatin structure to a repressive state. CtBP has been implicated in the repression of several genes (63) by interaction with DNA binding factors such as E1A or RIP140. Therefore we can hypothesize that the repression function of RREB-1 also would be mediated by the corepressor CtBP. On the contrary we found that RREB-1 is more acetylated in HLA-G-positive cells than in HLA-G-negative cells, a posttranscriptional modification previously implicated in the disruption of CtBP with E1A or RIP140 and mediated by CBP/p300 or pCAF (64 -66) . Therefore we can speculate that CtBP recruitment via RREB-1 would be dependent on CBP/p300. We are currently examining such a mechanism. It would be compatible with the role of CREB, CBP and P300 in HLA-G transactivation and facilitated by multiple CRE/TRE sites in the promoter region of HLA-G (28) and flanking CtBP binding sites.
Finally, we and other groups have demonstrated that DNA methylation is an important mechanism in repression of HLA-G expression (46, 67) . The present work thus suggests that RREB-1 and DNA methylation at the HLA-G locus are complementary mechanisms. We can also hypothesize that both mechanisms are closely involved in HLA-G transcriptional repression. Indeed, according to the present ChIP experiments, RREB-1 binding to the HLA-G promoter might be dependent or might be associated to the methylation status of the proximal promoter. Nonetheless EMSA and reporter luciferase experiments suggest that DNA methylation is not the necessary condition for the RREB-1 binding and repressive activity in M8 cells. However, we cannot exclude the fact that DNA methylation might enhance RREB-1 binding and thus repressive activity.
In conclusion, the proteomic approach used in this study allowed to define the first potential transcriptional repressor of HLA-G, which is RREB-1. Our results highlight the implication of RREB-1 in the transcriptional regulation of HLA-G gene and expand our understanding of the molecular mechanisms involved in this process. In particular we showed that nonacetylated RREB-1 recruits elements of CtBP complex implied in chromatin remodeling. Posttranscriptional modifications of RREB-1 thus appear to be key events in the regulation of HLA-G and remain to be investigated. These aspects would be useful in developing new strategies to modulate HLA-G expression in cancer therapies and transplantation.
